@article{ANCHONDO2025, 
author = {GAVIN M. ANCHONDO and KYRA PARKER and ALEXIS BRUCE and ELIZABETH CORTEZ and LE SU},
title = {The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma},
year = {2025},
journal = {Oncology Research},
volume = {33},
number = {5},
pages = {1001-1005},
keywords = {SS18-SSX, Synovial sarcoma, Targeted therapy},
url = {https://www.sciopen.com/article/10.32604/or.2025.060573},
doi = {10.32604/or.2025.060573},
abstract = {Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX. The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma, and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma, but emerging evidence suggests that upon depletion of SS18-SSX, an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival. In this article, we discuss the controversial roles of SS18-SSX’s transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of synovial sarcoma cells to SS18-SSX targeted therapeutics.}
}